Multiple Myeloma Faceoff: UT Southwestern vs Mayo Clinic
Two teams from leading institutions, UT Southwestern and the Mayo Clinic, go head-to-head to review the latest datasets in multiple myeloma management.
EP. 1: Team Introductions: MM Experts From UT Southwestern vs Mayo Clinic
Expert panelists from UT Southwestern and the Mayo Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent clinical trial data in relapsed/refractory multiple myeloma.
EP. 2: Relapsed/Refractory Multiple Myeloma: The KarMMa-3 Study
Expert Larry Anderson, Jr, MD, PhD, FACP, reviews data from the KarMMa-3 study of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
EP. 3: Cross Q&A: Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma
Panelists follow up with questions and comments on the KarMMa-3 study in relapsed/refractory multiple myeloma and consider how idecabtagene vicleucel might fit into real-world practice.
EP. 4: Relapsed/Refractory Multiple Myeloma: The CARTITUDE-4 Study
Key opinion leader Prashant Kapoor, MD, FACP, shares data from the CARTITUDE-4 study of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.
EP. 5: Cross Q&A: Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Experts from the Mayo Clinic and UT Southwestern share insight on the CARTITUDE-4 study and ciltacabtagene autoleucel in the second cross Q&A session.
EP. 6: Relapsed/Refractory Multiple Myeloma: The ALLIANCE A061202 Study
Adeel Khan, MD, MPH, MS, expert in multiple myeloma management, reviews data from the ALLIANCE A061202 trial of isatuximab + pomalidomide + dexamethasone in relapsed/refractory disease.
EP. 7: Cross Q&A: Isatuximab + Pom-Dex in Relapsed/Refractory Multiple Myeloma
Panelists from both the Mayo Clinic and UT Southwestern comment on data from ALLIANCE A061202 and consider the role of isatuximab in patients with relapsed/refractory multiple myeloma.
EP. 8: Relapsed/Refractory Multiple Myeloma: The IKEMA Study
Covering the first of two abstracts, Wilson Gonsalves, MD, reviews data from the IKEMA study of isatuximab KD in patients with relapsed/refractory multiple myeloma.
EP. 9: Biochemical vs Clinical Progression in Relapsed/Refractory Multiple Myeloma
Expert Wilson Gonsalves, MD, shares clinical data in multiple myeloma centered on the distinction between biochemical versus clinical progression.
EP. 10: Cross Q&A: Isa + KD in Relapsed/Refractory MM and Biochemical vs Clinical Progression
In the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.
